CV Sciences Q2 revenue $3.6M (-8% YoY); first positive adjusted EBITDA in six years

CV Sciences, Inc.

2025-Q2 EPS reported $0.00 revenue$7,226,000

Revenue $3.6M, down 8% from $4.0M in Q2 2024; units sold down 7%, avg price down 2.8%.
Gross margin 50.9%, highest since Q3 2019, up from 47.0% in Q2 2024.
Adjusted EBITDA positive $0.1M, first since Q2 2019, vs -$6k in Q2 2024.
Cash balance $0.9M at quarter end, up from $0.5M at end of 2024.
CEO cites state regulatory pressure for sales decline; pushing M&A and new products.

item 2.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.